Doximity, the leading digital platform for U.S. medical professionals, announced that it has acquired Pathway Medical Inc., a Montreal-based startup specialising in medical AI and evidence-based clinical reference.

Physicians make up half of Pathway’s team. Over the past seven years, they’ve assembled one of the largest structured datasets in medicine—purpose-built for AI—spanning nearly every guideline, drug, and landmark trial across all major specialities. Pathway’s model outperforms others in clinical accuracy, recently scoring a record 96 per cent on the U.S. Medical Licensing Examination (USMLE) benchmark.

“We’re thrilled to welcome the Pathway team to Doximity,” said Jeff Tangney, co-founder and CEO of Doximity. “They’ve painstakingly built one of the best datasets in medicine, and it’s going to take our clinical reference capabilities to an entirely new level.”

“There’s a growing need for clinical tools that combine trusted evidence with the speed and adaptability of AI,” said Jon Hershon, CEO of Pathway. “Hundreds of thousands of users have registered for Pathway, and thousands pay $300 per year for our premium product. With Doximity, one of the most trusted platforms in healthcare, we’re now bringing that experience to millions for free, built directly into the tools they already use at the point of care.”

The transaction closed on July 29, 2025, for cash consideration of $26 million and up to $37 million in additional equity grants.